🇺🇸 Grazoprevir/Elbasvir in United States
70 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 70
Most-reported reactions
- Hepatitis C — 26 reports (37.14%)
- Treatment Failure — 20 reports (28.57%)
- Virologic Failure — 6 reports (8.57%)
- Therapy Non-Responder — 5 reports (7.14%)
- Atrial Fibrillation — 3 reports (4.29%)
- Death — 2 reports (2.86%)
- Drug Interaction — 2 reports (2.86%)
- Hepatocellular Carcinoma — 2 reports (2.86%)
- Pathogen Resistance — 2 reports (2.86%)
- Rash — 2 reports (2.86%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is Grazoprevir/Elbasvir approved in United States?
Grazoprevir/Elbasvir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Grazoprevir/Elbasvir in United States?
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba is the originator. The local marketing authorisation holder may differ — check the official source linked above.